ADMdx Logo
Contact Us

Translate the brain's 
intricacy with
REMARKABLE
CLARITY

ADMdx is a leader in the
advanced use of imaging and 
other biomarkers to support the 
diagnosis and treatment of 
brain disorders

Defining clarity in diagnostics

At ADMdx, we’re applying advances in image measurement and analysis to support earlier, more accurate identification of brain disorders including Alzheimer’s disease and other dementias.

CorInsights® MRI, our first FDA 510k cleared product, is powered by ADMdx technology. This advanced reporting tool uses readily available MRI brain scans to support medical professionals in providing a new standard of care.
ADMdx_brain_quilling

Enabling success in clinical trials

ADMdx provides a full spectrum of imaging CRO services for CNS imaging trials using PET and MRI biomarkers, including:

  • Protocol input, charter and technical manual development
  • Imaging site identification and qualification
  • Central data receipt and quality control
  • Radiology reads
  • Advanced image processing and analysis
  • Reporting
  • Data management and archival

We support clinical trial success by combining key elements of CLARITY, QUALITY, PARTNER FOCUS, and INSIGHT.

Using our reference database and multivariate image classification, we address critical questions to support trial success:

  • Patient inclusion based upon:
    • Disease patterns
    • Pathology
  • Patient stratification for analysis, by predicting:
    • Rates of clinical decline
    • Pathology accumulation rates
  • Detection of treatment effect
  • Treatment responder characteristics

Learn more about our clinical trial capabilities.

Harnessing the power of  imaging for UNPARALLELED INSIGHTS

Using our reference database of over 30,000 PET and MRI scans with associated clinical and fluid biomarker data, and through long-standing collaborations with thought leaders from major institutions, ADMdx has characterized the effects of diseases and syndromes including:
  • Alzheimer’s disease progression from amyloid negative controls through amyloid and tau positive AD dementia
  • Atypical Alzheimer’s disease variants including Posterior Cortical Atrophy, amyloid positive Corticobasal Syndrome, and amyloid positive Logopenic Progressive Aphasia, and Early Onset Alzheimer’s Disease
  • Frontotemporal dementia variants including behavioral, semantic dementia, primary progressive aphasia, and nonfluent progressive aphasia
  • Traumatic brain injury
  • Parkinson’s disease
  • White matter / cerebrovascular disease
  • Down Syndrome

Join us for ongoing updates, including webinar sessions, group calls, user experience surveys and more.

PRIVACYCONTACT
©2021. CorInsights® MRI is a registered trademark of AMDdx, 555 Skokie Blvd, Suite 500, Northbrook, IL, 60062, USA.
ADMdx_brain_quilling

Interested in registering for our webinars beginning January 2022?

Submit your email below to be added to our invitation list